BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38050024)

  • 21. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma.
    Narita M; Hatano E; Arizono S; Miyagawa-Hayashino A; Isoda H; Kitamura K; Taura K; Yasuchika K; Nitta T; Ikai I; Uemoto S
    J Gastroenterol; 2009; 44(7):793-8. PubMed ID: 19404564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatic Adenoma Subtypes on Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI: Systematic Review and Meta-Analysis.
    Kim TH; Woo S; Ebrahimzadeh S; McInnes MDF; Gerst SR; Do RK
    AJR Am J Roentgenol; 2023 Jan; 220(1):28-38. PubMed ID: 35920706
    [No Abstract]   [Full Text] [Related]  

  • 23. Hepatocyte transporter expression in FNH and FNH-like nodule: correlation with signal intensity on gadoxetic acid enhanced magnetic resonance images.
    Yoneda N; Matsui O; Kitao A; Kita R; Kozaka K; Koda W; Kobayashi S; Gabata T; Ikeda H; Sato Y; Nakanuma Y
    Jpn J Radiol; 2012 Jul; 30(6):499-508. PubMed ID: 22618456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Value of discrepancy of the central scar-like structure between dynamic CT and gadoxetate disodium-enhanced MRI in differentiation of focal nodular hyperplasia and hepatocellular adenoma.
    Park HJ; Byun JH; Kang JH; Kang HJ; Yu E; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
    Eur J Radiol; 2021 Jun; 139():109730. PubMed ID: 33930719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A cost-effectiveness analysis of the diagnostic strategies for differentiating focal nodular hyperplasia from hepatocellular adenoma.
    Suh CH; Kim KW; Park SH; Shin S; Ahn J; Pyo J; Shinagare AB; Krajewski KM; Ramaiya NH
    Eur Radiol; 2018 Jan; 28(1):214-225. PubMed ID: 28726119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dynamic contrast-enhanced MRI of the liver in Mrp2-deficient rats using the hepatobiliary contrast agent Gd-EOB-DTPA.
    Saito S; Obata A; Kashiwagi Y; Abe K; Murase K
    Invest Radiol; 2013 Jul; 48(7):548-53. PubMed ID: 23442774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gadoxetic acid enhanced MRI for differentiation of FNH and HCA: a single centre experience.
    Grieser C; Steffen IG; Kramme IB; Bläker H; Kilic E; Perez Fernandez CM; Seehofer D; Schott E; Hamm B; Denecke T
    Eur Radiol; 2014 Jun; 24(6):1339-48. PubMed ID: 24658870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MRI for characterization of benign hepatocellular tumors on hepatobiliary phase: the added value of in-phase imaging and lesion-to-liver visual signal intensity ratio.
    Lebert P; Adens-Fauquembergue M; Azahaf M; Gnemmi V; Behal H; Luciani A; Ernst O
    Eur Radiol; 2019 Nov; 29(11):5742-5751. PubMed ID: 30993437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differentiation Between Hepatocellular Carcinoma Showing Hyperintensity on the Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI and Focal Nodular Hyperplasia by CT and MRI.
    Kitao A; Matsui O; Yoneda N; Kita R; Kozaka K; Kobayashi S; Gabata T
    AJR Am J Roentgenol; 2018 Aug; 211(2):347-357. PubMed ID: 29708786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhancement pattern of hepatocellular adenoma (HCA) on MR imaging performed with Gd-EOB-DTPA versus other Gd-based contrast agents (GBCAs): An intraindividual comparison.
    Cannella R; Brancatelli G; Rangaswamy B; Minervini MI; Borhani AA; Furlan A
    Eur J Radiol; 2019 Oct; 119():108633. PubMed ID: 31437747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Performance of Contrast-Enhanced Sonography Versus MRI With a Liver-Specific Contrast Agent for Diagnosis of Hepatocellular Adenoma and Focal Nodular Hyperplasia.
    Bröker MEE; Taimr P; de Vries M; Braun LMM; de Man RA; Ijzermans JNM; Dwarkasing RS
    AJR Am J Roentgenol; 2020 Jan; 214(1):81-89. PubMed ID: 31573852
    [No Abstract]   [Full Text] [Related]  

  • 32. OATP1B3 expression is strongly associated with Wnt/β-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma.
    Ueno A; Masugi Y; Yamazaki K; Komuta M; Effendi K; Tanami Y; Tsujikawa H; Tanimoto A; Okuda S; Itano O; Kitagawa Y; Kuribayashi S; Sakamoto M
    J Hepatol; 2014 Nov; 61(5):1080-7. PubMed ID: 24946283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatocellular adenomas: is there additional value in using Gd-EOB-enhanced MRI for subtype differentiation?
    Auer TA; Fehrenbach U; Grieser C; Penzkofer T; Geisel D; Schmelzle M; Müller T; Bläker H; Seehofer D; Denecke T
    Eur Radiol; 2020 Jun; 30(6):3497-3506. PubMed ID: 32086574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Morphologic and Molecular Features of Hepatocellular Adenoma with Gadoxetic Acid-enhanced MR Imaging.
    Ba-Ssalamah A; Antunes C; Feier D; Bastati N; Hodge JC; Stift J; Cipriano MA; Wrba F; Trauner M; Herold CJ; Caseiro-Alves F
    Radiology; 2015 Oct; 277(1):104-13. PubMed ID: 25985059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Value of Texture Analysis on Gadoxetic Acid-Enhanced MRI for Differentiating Hepatocellular Adenoma From Focal Nodular Hyperplasia.
    Cannella R; Rangaswamy B; Minervini MI; Borhani AA; Tsung A; Furlan A
    AJR Am J Roentgenol; 2019 Mar; 212(3):538-546. PubMed ID: 30557050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of volumetric contrast-enhanced and diffusion-weighted MRI in differentiating between common primary hypervascular liver tumors.
    Zarghampour M; Fouladi DF; Pandey A; Ghasabeh MA; Pandey P; Varzaneh FN; Khoshpouri P; Shao N; Pan L; Grimm R; Kamel IR
    J Magn Reson Imaging; 2018 Oct; 48(4):1080-1090. PubMed ID: 29630756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. OATP1B3 Expression in Hepatocellular Carcinoma Correlates with Intralesional Gd-EOB-DTPA Uptake and Signal Intensity on Gd-EOB-DTPA-Enhanced MRI.
    Zhou X; Long L; Mo Z; Li Y
    Cancer Manag Res; 2021; 13():1169-1177. PubMed ID: 33603462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging--correlation with molecular transporters and histopathologic features.
    Kitao A; Zen Y; Matsui O; Gabata T; Kobayashi S; Koda W; Kozaka K; Yoneda N; Yamashita T; Kaneko S; Nakanuma Y
    Radiology; 2010 Sep; 256(3):817-26. PubMed ID: 20663969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gadoxetic acid-enhanced MR imaging for hepatocellular carcinoma: molecular and genetic background.
    Kitao A; Matsui O; Yoneda N; Kozaka K; Kobayashi S; Koda W; Inoue D; Ogi T; Yoshida K; Gabata T
    Eur Radiol; 2020 Jun; 30(6):3438-3447. PubMed ID: 32064560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imaging modalities for focal nodular hyperplasia and hepatocellular adenoma.
    van den Esschert JW; van Gulik TM; Phoa SS
    Dig Surg; 2010; 27(1):46-55. PubMed ID: 20357451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.